Firm Advises Redesign Health on $65 Million Series C Financing
- Client Highlights
- Digital Health
- Life Sciences
On September 13, 2022, Redesign Health, a New York City-based company that builds other healthcare start-ups, closed a $65 million Series C funding round. The funding was led by General Catalyst, with other investors including CVS Health Ventures, UPMC Enterprises, Eden Global Partners, Euclidean Capital, Samsung Next, TriplePoint Capital, and Declaration Partners also participating. Wilson Sonsini Goodrich & Rosati advised Redesign Health on the transaction.
Founded in 2018, Redesign Health researches, assembles, brands, and launches healthcare start-ups by tapping into its team of entrepreneurs, healthcare industry operators, business analysts, and investors. To date, Redesign Health has launched more than 40 companies, including Ever/body, which focuses on cosmetic dermatology; cancer-care company Jasper; and metabolic health company Calibrate. According to the company’s founder and CEO, Brett Shaheen, Redesign Health plans to create more than 25 companies this year alone. The proceeds from the latest funding will benefit Redesign Health’s own operations and platform, rather than being doled out to the operating companies it has founded.
The Wilson Sonsini team that advised Redesign Health on the financing included Megan Baier, Seth Helfgott, Rob Broderick, Josh Bronstein, and Daniel Xo.
For more information, please see this Fast Company article.